Skip to content

The Effect of Intramuscular Injection and Local Addition of Esketamine on Depression and Cognitive Function in Elderly Patients After Vertebroplasty

The Effect of Intramuscular Injection and Local Addition of Esketamine on Depression and Cognitive Function in Elderly Patients After Vertebroplasty

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095649
Enrollment
Unknown
Registered
2025-01-09
Start date
2024-12-02
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Esk-IM Group:Thirty minutes prior to surgery, a 3 mL mixture containing 2 mg of midazolam and 25 mg of esketamine is injected into the gluteus maximus. For local anesthesia during the procedure, 20 mL
Esk-LA Group:Thirty minutes prior to surgery, 2 mL of midazolam (2 mg) is injected into the gluteus maximus. For local anesthesia during the procedure, a 20 mL mixture of 1% lidocaine and 25 mg of esk
Control Group:Thirty minutes prior to surgery, 2 mL of midazolam (2 mg) is injected into the gluteus maximus. For local anesthesia during the procedure, 20 mL of 1% lidocaine is administered.

Sponsors

Ningbo Medical Center Lihuili Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients undergoing percutaneous kyphoplasty of the lumbar or thoracic spine. 2.Age between 60 and 80 years. 3.American Society of Anesthesiologists (ASA) classification I–III. 4.Body Mass Index (BMI) between 18.5 and 25 kg/m^2. 5.Montreal Cognitive Assessment (MoCA) score >= 18. 6.Patient Health Questionnaire (PHQ-9) score <= 9.

Exclusion criteria

Exclusion criteria: 1.Allergy to lidocaine. 2.Patients deemed unable to undergo surgery under local anesthesia by the surgeon. 3.Patients with severe cognitive impairment unable to complete relevant assessments (MoCA score = 10) or other severe psychiatric disorders (e.g., bipolar disorder, schizophrenia).

Design outcomes

Primary

MeasureTime frame
PHQ-9 Score;MoCA Score;

Secondary

MeasureTime frame
VAS Score;Intraoperative MAP (Mean Arterial Pressure);Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) Scale; Adverse Reactions;Changes in s100ß;Intraoperative heart rate;8-OHdG;WBC level;CRP;IL-6;Blood cortisol;

Countries

China

Contacts

Public ContactLongyuan Zhou

Ningbo Medical Center Lihuili Hospital

396919647@qq.com+86 158 6721 2308

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026